Rachel M. Bartlett
Papers
1
Total Citations
37
H-Index
1
About
Dr. Rachel M. Bartlett is a leading researcher in molecular imaging, with a primary focus on the noninvasive assessment of tumor hypoxia. Her work is critical for improving cancer diagnosis and treatment planning, as hypoxia is a key driver of therapy resistance. Dr. Bartlett’s major contribution lies in rigorously validating imaging biomarkers, particularly through the use of positron emission tomography (PET). Her most-cited study, with 37 citations, directly addresses a central challenge in the field: the accuracy of \(^{18}\text{F}\)-fluoromisonidazole (\(^{18}\text{F}\)-FMISO) PET. By correlating dynamic small-animal PET data with direct, image-guided oxygen probe measurements in rats, she provided a crucial experimental benchmark for interpreting \(^{18}\text{F}\)-FMISO signals. This work demonstrated that kinetic analysis of dynamic PET data can yield a more reliable reflection of true tissue oxygenation than static imaging alone. Through this meticulous, translational approach, Dr. Bartlett has helped establish a more robust framework for using PET to map hypoxia, directly impacting how researchers and clinicians evaluate tumor physiology and the efficacy of hypoxia-targeted therapies.
Research Focus
Key Achievements
Top Papers
- 1